京新药业(002020) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was CNY 927.29 million, an increase of 11.01% compared to CNY 835.31 million in the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was CNY 174.70 million, reflecting a growth of 9.66% from CNY 159.31 million year-on-year[6]. - The net cash flow from operating activities for the year-to-date period was CNY 446.51 million, up 16.46% from CNY 384.99 million in the previous year[6]. - The company's basic earnings per share remained stable at CNY 0.20, with a diluted earnings per share also at CNY 0.20[6]. - The company reported a net profit margin improvement, with net profit for the period increasing due to higher revenue and controlled costs[25]. - The net profit for the current period is 475,470,952.50, an increase from 440,185,520.85 in the previous period, representing a growth of approximately 8%[27]. - Operating profit for the current period is 533,943,335.85, compared to 486,661,837.14 in the previous period, indicating an increase of about 10%[27]. - The total profit for the current period is 532,781,444.69, compared to 488,259,200.58 in the previous period, indicating an increase of about 9%[27]. Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 7,013.43 million, representing a 5.98% increase from CNY 6,617.70 million at the end of the previous year[6]. - The company's total liabilities reached ¥2,021,985,295.16, up from ¥1,639,127,704.24, reflecting an increase of 23.4%[22]. - The total equity attributable to shareholders was CNY 4,967.43 million, showing a slight increase of 0.18% from CNY 4,958.33 million in the previous year[6]. - The total equity attributable to shareholders was ¥4,967,428,026.10, a slight increase from ¥4,958,326,790.13[24]. Cash Flow - The net cash flow from operating activities surged by 382.27% to ¥681,416,066.30, driven by increased sales revenue and improved collection of accounts receivable[11]. - Cash flow from operating activities for the current period is 681,416,066.30, significantly up from 141,293,758.40 in the previous period, showing a substantial improvement[31]. - The net cash flow from investing activities is -617,421,539.09, a decrease from 277,295,528.25 in the previous period, indicating a negative trend[31]. - The net cash flow from financing activities is -181,848,325.22, compared to 81,552,926.87 in the previous period, reflecting a decline[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,299[15]. - The largest shareholder, Lü Gang, holds 20.77% of the shares, totaling 178,796,755 shares[15]. Operating Costs and Expenses - Total operating costs for the third quarter of 2022 were ¥2,300,367,857.99, up from ¥2,124,942,041.95, reflecting a year-over-year increase of 8.3%[25]. - Research and development expenses for the third quarter of 2022 amounted to ¥246,403,668.53, compared to ¥227,892,721.46 in the previous year, indicating an increase of 8.1%[25]. - The company's financial expenses decreased by 125.93% to -¥59,376,378.44, mainly due to increased interest income from time deposits and exchange gains[11]. - The company reported a 746.30% increase in non-operating expenses to ¥2,179,982.31, primarily due to an increase in bad debt write-offs[11]. Asset Composition - Current assets totaled ¥3,271,012,226.99 as of September 30, 2022, slightly down from ¥3,292,888,604.35 at the end of the previous year[22]. - Non-current assets increased to ¥3,742,419,718.96 from ¥3,324,808,506.47, marking a significant rise of 12.5%[22]. - Cash and cash equivalents decreased to ¥1,543,092,081.54 from ¥1,558,668,597.33, a decline of 1%[22]. - Cash and cash equivalents at the end of the period amount to 1,401,844,562.75, slightly up from 1,391,803,166.97 in the previous period[31].